title: Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001.
abstract: Adenovirus infection is a serious and often fatal complication in hematopoietic stem cell transplant patients. There are currently no FDA-approved therapies for adenovirus infection, with only anecdotal, off-label uses described for a variety of anti-viral agents or immune therapies. We report the first case of successful eradication of disseminated adenovirus infection by the novel antiviral agent CMX001 in a severely immunocompromised pediatric stem cell transplant recipient following failure to respond to intravenous cidofovir. Complete clinical and virologic response was documented; virologic and pharmacokinetic data are reported. CMX001 is a promising new oral antiviral agent under development for the prophylaxis and treatment of severe infections caused by double-stranded DNA viruses including adenovirus in immunocompromised patients.
authors.affiliation: Department of Infectious Diseases, Walter Reed Army Medical Center, Washington, DC, USA.
authors.forename: Kris
authors.initials: K
authors.lastname: Paolino
authors.forename: Jane
authors.initials: J
authors.lastname: Sande
authors.forename: Evelio
authors.initials: E
authors.lastname: Perez
authors.forename: Brett
authors.initials: B
authors.lastname: Loechelt
authors.forename: Barbara
authors.initials: B
authors.lastname: Jantausch
authors.forename: Wendy
authors.initials: W
authors.lastname: Painter
authors.forename: Margaret
authors.initials: M
authors.lastname: Anderson
authors.forename: Tim
authors.initials: T
authors.lastname: Tippin
authors.forename: E Randall
authors.initials: ER
authors.lastname: Lanier
authors.forename: Terry
authors.initials: T
authors.lastname: Fry
authors.forename: Roberta L
authors.initials: RL
authors.lastname: DeBiasi
mesh_terms: D000258:Adenovirus Infections, Human / Q000150:complications / Q000188:drug therapy*; D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D003596:Cytosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016867:Immunocompromised Host; D063065:Organophosphonates / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; C525733:brincidofovir; D003596:Cytosine